Analysed ARCUTIS BIOTHERAPEUTICS INC (ARQT:NASDAQ) News Sources
Arcutis Biotherapeutics (ARQT) Presents Positive Phase 2 Data for ZORYVE Cream in Infants
19-04-2026
yahoo.com
Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
15-04-2026
yahoo.com
Arcutis Biotherapeutics Targets ZORYVE Expansion, Raises 2026 Outlook and Turns Cash-Flow Positive
15-04-2026
marketbeat.com
Is It Too Late To Revisit Arcutis Biotherapeutics (ARQT) After A 75% One-Year Surge?
08-04-2026
yahoo.com
Arcutis Stock Up 65% as Director Sells 10,000 Shares Under 10b5-1 Plan. Here's What Investors Should Know
08-04-2026
fool.com
How The Arcutis Biotherapeutics (ARQT) Story Is Evolving As Analysts Cluster Around US$35 Targets
08-04-2026
yahoo.com
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
07-04-2026
yahoo.com
Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference
31-03-2026
yahoo.com
Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting
28-03-2026
yahoo.com
What is the current price of ARCUTIS BIOTHERAPEUTICS INC (ARQT:NASDAQ)?
The current price of ARCUTIS BIOTHERAPEUTICS INC (ARQT:NASDAQ) is $24.54.
ARCUTIS BIOTHERAPEUTICS INC (ARQT:NASDAQ) absolute price change since previous trading day?
The absolute price change of ARCUTIS BIOTHERAPEUTICS INC (ARQT:NASDAQ) since the previous trading day is $0.35.
ARCUTIS BIOTHERAPEUTICS INC (ARQT:NASDAQ) percentage price change since previous trading day?
The percentage price change of ARCUTIS BIOTHERAPEUTICS INC (ARQT:NASDAQ) since the previous trading day is 1.4469%.
What is the most recent average sentiment score for ARCUTIS BIOTHERAPEUTICS INC (ARQT:NASDAQ)?
The most recent average sentiment score for ARCUTIS BIOTHERAPEUTICS INC (ARQT:NASDAQ) is 79 out of 100.
What is the most recent average sentiment for ARCUTIS BIOTHERAPEUTICS INC (ARQT:NASDAQ)?
The most recent sentiment for ARCUTIS BIOTHERAPEUTICS INC (ARQT:NASDAQ) is .
SEC-8K** Filing Available For ARCUTIS BIOTHERAPEUTICS INC (ARQT:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.